SPY756.62−0.42%QQQ686.17−0.61%BTC/USD71,511.00−3.27%DIA524.31−0.02%GLD356.89−2.27%TLT80.65−0.34%

Neurocrine Biosciences Inc

NBIXNASDAQ

Trade with Public

$172.49

-1.92-1.1%

Last update: Nov 12, 9:39 AM

Overview News Charts Earnings Forecast EventsPrice TargetsFinancials Sentiment Ownership Compare Options Stock Report

Neurocrine Biosciences (NBIX) Stock Price Target 2026

See analyst price targets, ratings and recent upgrades and downgrades for Neurocrine Biosciences (NBIX) stock.

Analyst Consensus — 23 Analysts

21Buy

2Hold

# Analysts23

Latest Upgrades and Downgrades for Neurocrine Biosciences Stock

See all ratings →

Date	Firm	Analyst	Action	Rating Change	Price Target
—	Guggenheim	Delma Caiati	PT Raise	Buy	$207→$224
—	Piper Sandler	David Amsellem	PT Raise	Overweight	$210→$215
—	Morgan Stanley	Jeffrey Hung	PT Raise	Equal-Weight	$183→$185
—	RBC Capital	Brian Abrahams	PT Raise	Outperform	$187→$190
—	Canaccord Genuity	Sumant Kulkarni	PT Raise	Buy	$210→$220
—	Needham	Ami Fadia	Maintained	Buy	$204
—	BMO Capital	Evan Seigerman	PT Cut	Market Perform	$164→$150
—	Guggenheim	Delma Caiati	Assumes	Buy	$207
—	UBS	Ashwani Verma	PT Cut	Buy	$231→$214
—	Morgan Stanley	Jeffrey Hung	PT Raise	Equal-Weight	$182→$183
—	RBC Capital	Brian Abrahams	Maintained	Outperform	$198
—	Citigroup	Yigal Nochomovitz	PT Raise	Buy	$249→$253
—	Morgan Stanley	Jeffrey Hung	PT Cut	Equal-Weight	$196→$182
—	Canaccord Genuity	Sumant Kulkarni	PT Raise	Buy	$200→$210
—	Truist Securities	Danielle Brill	PT Raise	Buy	$200→$213
—	Wedbush	Laura Chico	PT Raise	Outperform	$185→$194
—	Citigroup	Yigal Nochomovitz	PT Raise	Buy	$246→$249
—	RBC Capital	Brian Abrahams	PT Raise	Outperform	$195→$198
—	Morgan Stanley	Jeffrey Hung	PT Raise	Equal-Weight	$193→$196
—	TD Cowen	Phil Nadeau	PT Raise	Buy	$200→$220

Neurocrine Biosciences Inc

Neurocrine Biosciences (NBIX) Stock Price Target 2026

Latest Upgrades and Downgrades for Neurocrine Biosciences Stock

Neurocrine Biosciences (NBIX) Stock Price Target 2026

Latest Upgrades and Downgrades for Neurocrine Biosciences Stock

Analyst Ratings News

PRO
Guggenheim Maintains Buy on Neurocrine Biosciences, Raises Price Target to $224

PRO
Morgan Stanley Maintains Equal-Weight on Neurocrine Biosciences, Raises Price Target to $185

PRO
RBC Capital Maintains Outperform on Neurocrine Biosciences, Raises Price Target to $190

PRO
Canaccord Genuity Maintains Buy on Neurocrine Biosciences, Raises Price Target to $220

PRO
Piper Sandler Maintains Overweight on Neurocrine Biosciences, Raises Price Target to $215

PRO
Needham Reiterates Buy on Neurocrine Biosciences, Maintains $204 Price Target

People Also Watch

People Also Watch

Analyst Ratings News

PRO
Guggenheim Maintains Buy on Neurocrine Biosciences, Raises Price Target to $224

PRO
Morgan Stanley Maintains Equal-Weight on Neurocrine Biosciences, Raises Price Target to $185

PRO
RBC Capital Maintains Outperform on Neurocrine Biosciences, Raises Price Target to $190

PRO
Canaccord Genuity Maintains Buy on Neurocrine Biosciences, Raises Price Target to $220

PRO
Piper Sandler Maintains Overweight on Neurocrine Biosciences, Raises Price Target to $215

PRO
Needham Reiterates Buy on Neurocrine Biosciences, Maintains $204 Price Target

Neurocrine Biosciences Inc

Neurocrine Biosciences (NBIX) Stock Price Target 2026

Latest Upgrades and Downgrades for Neurocrine Biosciences Stock

Neurocrine Biosciences (NBIX) Stock Price Target 2026

Latest Upgrades and Downgrades for Neurocrine Biosciences Stock

Analyst Ratings News

PROGuggenheim Maintains Buy on Neurocrine Biosciences, Raises Price Target to $224

PROMorgan Stanley Maintains Equal-Weight on Neurocrine Biosciences, Raises Price Target to $185

PRORBC Capital Maintains Outperform on Neurocrine Biosciences, Raises Price Target to $190

PROCanaccord Genuity Maintains Buy on Neurocrine Biosciences, Raises Price Target to $220

PROPiper Sandler Maintains Overweight on Neurocrine Biosciences, Raises Price Target to $215

PRONeedham Reiterates Buy on Neurocrine Biosciences, Maintains $204 Price Target

People Also Watch

People Also Watch

Analyst Ratings News

PROGuggenheim Maintains Buy on Neurocrine Biosciences, Raises Price Target to $224

PROMorgan Stanley Maintains Equal-Weight on Neurocrine Biosciences, Raises Price Target to $185

PRORBC Capital Maintains Outperform on Neurocrine Biosciences, Raises Price Target to $190

PROCanaccord Genuity Maintains Buy on Neurocrine Biosciences, Raises Price Target to $220

PROPiper Sandler Maintains Overweight on Neurocrine Biosciences, Raises Price Target to $215

PRONeedham Reiterates Buy on Neurocrine Biosciences, Maintains $204 Price Target

PRO
Guggenheim Maintains Buy on Neurocrine Biosciences, Raises Price Target to $224

PRO
Morgan Stanley Maintains Equal-Weight on Neurocrine Biosciences, Raises Price Target to $185

PRO
RBC Capital Maintains Outperform on Neurocrine Biosciences, Raises Price Target to $190

PRO
Canaccord Genuity Maintains Buy on Neurocrine Biosciences, Raises Price Target to $220

PRO
Piper Sandler Maintains Overweight on Neurocrine Biosciences, Raises Price Target to $215

PRO
Needham Reiterates Buy on Neurocrine Biosciences, Maintains $204 Price Target

PRO
Guggenheim Maintains Buy on Neurocrine Biosciences, Raises Price Target to $224

PRO
Morgan Stanley Maintains Equal-Weight on Neurocrine Biosciences, Raises Price Target to $185

PRO
RBC Capital Maintains Outperform on Neurocrine Biosciences, Raises Price Target to $190

PRO
Canaccord Genuity Maintains Buy on Neurocrine Biosciences, Raises Price Target to $220

PRO
Piper Sandler Maintains Overweight on Neurocrine Biosciences, Raises Price Target to $215

PRO
Needham Reiterates Buy on Neurocrine Biosciences, Maintains $204 Price Target